CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 22 enrolled
Drug / intervention
NYX-2925 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03249103
NCT03249103Phase 2Completed
CompareCT.gov

A Phase 2, Single-Blind, Exploratory, Placebo-controlled, Pilot Study to Assess the Efficacy and Safety of Daily Oral NYX-2925 in Subjects With Fibromyalgia

Aptinyx·interventional·Posted Aug 15, 2017·Updated Sep 16, 2022

In Brief

A Phase 2 clinical trial evaluating NYX-2925 and Placebo oral capsule for Fibromyalgia. Completed, enrolled 22 participants across 2 sites.

Detailed Summary

The primary objective is to determine whether daily dosing with NYX-2925 changes markers of central pain processing in subjects with fibromyalgia by evaluating changes in evoked pain, and visual stimulation, functional magnetic resonance imaging (fMRI), resting state function connectivity magnetic resonance imaging (rs-fcMRI) and proton magnetic resonance spectroscopy (H-MRS) in fibromyalgia subjects on active drug versus placebo.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsFibromyalgia
CountriesUnited States
CollaboratorsinVentiv Health Clinical

Timeline

Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedAug 15, 2017
Enrollment StartAug 14, 2017
Primary CompletionApr 18, 2019
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 8.9 years ago

Interventions

NYX-2925drug

NYX-2925 is a novel small molecule that modulates the N-methyl-D-aspartate receptor (NMDAR).

Placebo oral capsuledrug

Matching placebo capsules.